Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
UBS
Deloitte
Teva
Chubb
McKinsey

Generated: March 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EPINASTINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Epinastine Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00407927 A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis Completed Merck Sharp & Dohme Corp. Phase 2 The purpose of this trial is to determine the safety, efficacy and tolerability of two doses of the study drug compared to placebo for the treatment of subjects with seasonal allergic rhinitis.
NCT00489398 Comparison of CL Wear Between Two Allergy Drops Withdrawn Merck Sharp & Dohme Corp. Phase 4 Comparison of two allergy drops for enhancing comfort and performance of contact lens wear
NCT00489398 Comparison of CL Wear Between Two Allergy Drops Withdrawn Hom, Milton M., OD, FAAO Phase 4 Comparison of two allergy drops for enhancing comfort and performance of contact lens wear
NCT00564421 Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648) Completed Merck Sharp & Dohme Corp. Phase 3 The purpose of this study is to determine the safety and efficacy of epinastine nasal spray compared to placebo for the treatment of subjects with seasonal allergic rhinitis
NCT01382654 Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis Completed Merck Sharp & Dohme Corp. Phase 2 The objectives of this study were to: - Examine the tolerability of two formulations and two dose concentrations of epinastine. - Select formulation(s) of epinastine for future studies by evaluating the individual sensory attribute scores of the Nasal Spray Evaluation Questionnaire (NSEQ) collected after each study drug administration and the subject preference ranking assessed at the completion of the study. - Compare the preference of two formulations and two dose concentrations of epinastine compared to azelastine following a single dose of each in a randomized, double-blind, two-cohort, three-period crossover design.
NCT01569191 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed University of Worcester Phase 4 Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many people, caused by hypersensitivity to normally harmless substances such as pollen, and often accompanies seasonal hay fever. Treatments that can be used before initiating medical therapy include artificial tear supplements (ATS) and cold compresses (CC). However, there is no evidence in the scientific literature that demonstrates their efficacy compared to no treatment or their combined effect with anti-allergic medication. Therefore the investigators aim to examine the efficacy of ATS and CC alone, in comparison to anti-allergic medication, and CC in combination with anti-allergic medication. In addition, the investigators also aim to determine the time course of ocular allergic reactions. At the end of the study the investigators will be able to see whether or not ATS and CC are effective in treating SAC.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Epinastine Hydrochloride

Condition Name

Condition Name for Epinastine Hydrochloride
Intervention Trials
Rhinitis, Allergic, Perennial 4
Healthy 3
Allergic Conjunctivitis 2
Seasonal Allergic Rhinitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Epinastine Hydrochloride
Intervention Trials
Rhinitis, Allergic 7
Rhinitis 7
Rhinitis, Allergic, Perennial 4
Conjunctivitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Epinastine Hydrochloride

Trials by Country

Trials by Country for Epinastine Hydrochloride
Location Trials
United Kingdom 1
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Epinastine Hydrochloride
Location Trials
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Epinastine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Epinastine Hydrochloride
Clinical Trial Phase Trials
Phase 4 3
Phase 3 4
Phase 2 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Epinastine Hydrochloride
Clinical Trial Phase Trials
Completed 14
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Epinastine Hydrochloride

Sponsor Name

Sponsor Name for Epinastine Hydrochloride
Sponsor Trials
Boehringer Ingelheim 9
Merck Sharp & Dohme Corp. 4
Aston University 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Epinastine Hydrochloride
Sponsor Trials
Industry 14
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
US Army
Merck
Express Scripts
Johnson and Johnson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.